Federated Hermes Inc. Sells 3,126 Shares of Moderna, Inc. (NASDAQ:MRNA)

Federated Hermes Inc. reduced its stake in Moderna, Inc. (NASDAQ:MRNA) by 62.8% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 1,854 shares of the company’s stock after selling 3,126 shares during the period. Federated Hermes Inc.’s holdings in Moderna were worth $184,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also made changes to their positions in MRNA. Arlington Trust Co LLC increased its stake in shares of Moderna by 4,833.3% during the fourth quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock valued at $29,000 after purchasing an additional 290 shares in the last quarter. GPS Wealth Strategies Group LLC increased its stake in shares of Moderna by 54.1% during the third quarter. GPS Wealth Strategies Group LLC now owns 513 shares of the company’s stock valued at $53,000 after purchasing an additional 180 shares in the last quarter. Archer Investment Corp increased its stake in shares of Moderna by 71.2% during the third quarter. Archer Investment Corp now owns 534 shares of the company’s stock valued at $55,000 after purchasing an additional 222 shares in the last quarter. Parkside Financial Bank & Trust increased its stake in shares of Moderna by 44.9% during the third quarter. Parkside Financial Bank & Trust now owns 565 shares of the company’s stock valued at $58,000 after purchasing an additional 175 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its stake in shares of Moderna by 408.3% during the third quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 610 shares of the company’s stock valued at $63,000 after purchasing an additional 490 shares in the last quarter. Institutional investors own 75.33% of the company’s stock.

Insider Activity at Moderna

In related news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $108.54, for a total transaction of $1,628,100.00. Following the completion of the sale, the director now owns 2,131,931 shares in the company, valued at $231,399,790.74. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Moderna news, Director Noubar Afeyan sold 15,000 shares of the business’s stock in a transaction dated Wednesday, March 13th. The stock was sold at an average price of $108.54, for a total transaction of $1,628,100.00. Following the completion of the sale, the director now owns 2,131,931 shares of the company’s stock, valued at $231,399,790.74. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO James M. Mock sold 705 shares of the business’s stock in a transaction dated Monday, April 8th. The shares were sold at an average price of $101.93, for a total value of $71,860.65. Following the sale, the chief financial officer now directly owns 5,048 shares of the company’s stock, valued at approximately $514,542.64. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 139,954 shares of company stock worth $14,822,576. 15.70% of the stock is owned by insiders.

Moderna Stock Down 0.5 %

Moderna stock opened at $125.00 on Monday. The stock has a market cap of $47.86 billion, a PE ratio of -7.98 and a beta of 1.57. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 4.03. Moderna, Inc. has a one year low of $62.55 and a one year high of $142.79. The stock has a fifty day moving average of $105.05 and a 200 day moving average of $94.48.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, beating analysts’ consensus estimates of ($3.59) by $0.52. The company had revenue of $167.00 million during the quarter, compared to analysts’ expectations of $93.26 million. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. Moderna’s revenue for the quarter was down 91.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.19 earnings per share. As a group, sell-side analysts predict that Moderna, Inc. will post -7.47 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have weighed in on MRNA shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research note on Thursday. Canaccord Genuity Group increased their price target on shares of Moderna from $91.00 to $106.00 and gave the company a “hold” rating in a report on Friday. HSBC reiterated a “reduce” rating and set a $86.00 price target (up previously from $75.00) on shares of Moderna in a report on Monday, February 26th. William Blair reiterated a “market perform” rating on shares of Moderna in a report on Monday, April 1st. Finally, Oppenheimer upped their price target on Moderna from $142.00 to $163.00 and gave the company an “outperform” rating in a report on Friday. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, Moderna currently has an average rating of “Hold” and an average target price of $129.55.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.